Cover Image

Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies

Abstract

Product Description

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis

The apoptosis report part comprises defined and up to date development strategies for 171 apoptotic drugs in oncology (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. This report part extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target strategies, and assesses them in 53 different cancer indications.

Part II: Cancer Vaccines

The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.

Part III: Antibodies

The cancer antibody drug report part comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug' s properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Table of Contents

Key Topics Covered:

Part I: Apoptosis

  • 5.1 The Scope of this Report
  • 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets)
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs)
  • 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies)
  • 9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications)
  • 10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators)
  • 12 Drug Index
  • 13 Company Index

Part II: Cancer Vaccines

  • 5.1 The Scope of this Report
  • 6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets)
  • 7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs)
  • 8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies)
  • 9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications)
  • 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators)
  • 11 Disclaimer
  • 12 Drug Index
  • 13 Company Index

Part III: Antibodies

  • 5.1 The Scope of this Report
  • 6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (255 Drug Targets)
  • 7 Emerging New Products to Established Ones: Drug Target Strategies of Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug Targets Strategies and 531 Antibody Drugs)
  • 8 Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications)
  • 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531 Antibody Drugs)
  • 10 Disclaimer
  • 11 Drug Index
  • 12 Company Index

Featured Companies

This Report Includes the Following Companies:

  • A&G Pharmaceutical
  • Abbott
  • Abiogen
  • Ablynx
  • AC Immune
  • Acceleron Pharma
  • Access
  • Actinium Pharmaceuticals
  • Active Biotech
  • Adaptimmune
  • Adherex
  • Aduro BioTech
  • Advanced Life Sciences
  • Advaxis
  • AEgera
  • AEterna Zentaris
  • Affibody
  • Affimed Therapeutics
  • Affitech
  • AGY Therapeutics
  • Aida Pharmaceuticals
  • Akela Pharma
  • Alder Biopharmaceuticals
  • Alethia Biotherapeutics
  • Alexion
  • Alfacell
  • Algeta
  • AlphaVax
  • ALSP
  • Altor BioScience
  • Ambrilia Biopharma
  • Amgen
  • Amorfix Life Sciences
  • Anavex Life Sciences
  • Antisoma
  • Aphios
  • ApopLogic Pharmaceuticals
  • Apricus Biosciences
  • Apthera
  • Arana Therapeutics
  • Arca biopharma
  • arGEN-X
  • Arno Therapeutics
  • ArQule
  • Ascenta Therapeutics
  • Astellas
  • AstraZeneca
  • Attenuon
  • Avaxia
  • AVEO
  • AVI BioPharma
  • Bavarian Nordic
  • Bayer
  • Bellicum Pharmaceuticals
  • Berkeley Lab
  • BioAxone
  • Biocon
  • Biogen Idec
  • BioInvent
  • Biolex
  • BioLineRx
  • Bionovo
  • Biosceptre
  • Biostar
  • Biotecnol
  • Biotest
  • BioVex
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG
  • Cadila
  • Cancer Innovations
  • Cancer Research Technology
  • Cell Genesys
  • Celldex Therapeutics
  • Celltrion
  • Celtic Pharma
  • Center of Molecular Immunology
  • Cephalon
  • CG Therapeutics
  • ChemoCentryx
  • Circadian Technologies
  • Coronado Biosciences
  • Cosmo Pharmaceuticals
  • Critical Outcome Technologies
  • CSL
  • CuraGen
  • CureTech
  • Curis
  • Cyclacel
  • Cylene Pharmaceuticals
  • CytImmune Sciences
  • Cytochroma
  • Daewoong
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Dendreon
  • DeveloGen
  • DiaMedica
  • Dompe
  • Dr Reddy' s
  • Dyax
  • Eisai
  • Elan
  • Eleos
  • Eli Lilly
  • Emergent BioSolutions
  • EntreMed
  • Enzon
  • Epeius Biotechnologies
  • EpiCept
  • Epitomics
  • EUSA Pharma
  • Exelixis
  • Faron Pharmaceuticals
  • Favrille
  • Femta Pharmaceuticals
  • FibroGen
  • Five Prime Therapeutics
  • Fusion Antibodies
  • Galaxy Biotech
  • GammaCan
  • Ganymed Pharmaceuticals
  • Gene Techno Science
  • Genencor
  • Genentech
  • Generex
  • Genmab
  • GenOdyssee Pharmaceuticals
  • Genomic Systems
  • GenPat77
  • Genta
  • GENTICEL
  • Genzyme
  • Geron
  • Gilead Sciences
  • GlaxoSmithKline
  • Gliknik
  • GlobeImmune
  • GlycoGenesys
  • Glycotope
  • Gradalis
  • Green Cross
  • Hawthorn Pharmaceuticals
  • Hoffmann-La Roche
  • Human Genome Sciences
  • Ichor Medical Systems
  • Idera Pharmaceuticals
  • IDM Pharma
  • ImClone Systems
  • IMED
  • Immune Pharmaceuticals
  • ImmunoCellular Therapeutics
  • ImmunoFrontier
  • ImmunoGen
  • Immunomedics
  • Immunotope
  • Immutep
  • Infinity Pharmaceuticals
  • Innate Pharma
  • InNexus Biotechnology
  • Inovio
  • Insmed
  • Intracel
  • Intradigm
  • Introgen Therapeutics
  • ISA Pharmaceuticals
  • Isis Pharmaceuticals
  • ISU ABXIS
  • Johnson & Johnson
  • Kaketsuken
  • KaloBios
  • Kalypsys
  • Kirin Pharma
  • Kissei
  • Kyowa Hakko Kirin
  • Kyto Biopharma
  • LFB Biotechnologies
  • LG Life Sciences
  • Lorus Therapeutics
  • MacroGenics
  • MAT Biopharma
  • Medarex
  • Medical Marketing International
  • MediGene
  • MedImmune
  • Medisyn Technologies
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Merrimack
  • MethylGene
  • Micromet
  • Mitsubishi Tanabe Pharma
  • MolMed
  • Mologen
  • Mycenax
  • Nemod Biotherapeutics
  • NeoPharm
  • Neovacs
  • Neuren
  • NIH
  • Nippon Shinyaku
  • NKT Therapeutics
  • Non-industrial source
  • Northwest Biotherapeutics
  • Novacea
  • Novartis
  • NovaRx
  • Novelix
  • Novogen
  • OncoMed
  • OncoMune
  • Onconova
  • OncoTherapy Science
  • Oncothyreon
  • Oncovir
  • Onyvax
  • OSI Pharmaceuticals
  • Oxford BioMedica
  • OXiGENE
  • Paladin Labs
  • Panacea
  • PanaGin
  • PanGenetics
  • Patrys
  • Pepscan Systems
  • Pepscan Therapeutics
  • Peregrine Pharmaceuticals
  • Perseus Proteomics
  • Pfizer
  • Pharmacyclics
  • PharmaMar
  • Pharmexa
  • Pharminox
  • Philogen
  • Pierre Fabre
  • Prima Biomed
  • ProCell Therapeutics
  • Prochon Biotech
  • Progenics Pharmaceuticals
  • Protherics
  • Radient Pharmaceuticals
  • Ramot
  • Reata Pharmaceuticals
  • Recepta biopharma
  • Receptor BioLogix
  • Regeneron
  • Regulon
  • responsif
  • Sanofi-Aventis
  • Santaris Pharma
  • SBI Biotech
  • Scancell
  • SciClone Pharmaceuticals
  • Seattle Genetics
  • Semafore Pharmaceuticals
  • Shenogen
  • Sigma-Tau
  • SRI International
  • Stainwei Biotech
  • Sunol Molecular
  • SuperGen
  • SuppreMol
  • Switch Pharma
  • Symbiotec
  • Symphogen
  • Synageva BioPharma
  • SynerGene Therapeutics
  • Takeda
  • TapImmune
  • Targa Therapeutics
  • Taxolog
  • TeGenero
  • Telik
  • Teva
  • Thallion Pharmaceuticals
  • Therapure Biopharma
  • Therion Biologics
  • ThromboGenics
  • Tigris Pharmaceuticals
  • Titan Pharmaceuticals
  • Tolerx
  • TopoTarget
  • Tracon Pharmaceuticals
  • Transgene
  • Trillium Therapeutics
  • Trion Pharma
  • UCB
  • United Biomedical
  • United Therapeutics
  • Vaccinex
  • Wakunaga
  • Vascular Biogenics
  • VasGene Therapeutics
  • Vaxil BioTherapeutics
  • Vaxon Biotech
  • VaxOnco
  • Vectura
  • Vertex Pharmaceuticals
  • Vical
  • Wilex
  • VioQuest
  • Viragen
  • Viralytics
  • Virionics
  • ViroMed
  • ViroTarg
  • Viventia Biotech
  • XBiotech
  • Xencor
  • Xerion
  • Xoma
  • Y' s Therapeutics
  • YM BioSciences
  • Zenotech
  • Zensun
  • ZymoGenetics

Featured Drugs

A Shortlist of Drugs Included are:

  • 131I-tositumomab
  • 2-methoxyestradiol
  • abagovomab
  • ABT-263
  • ADXS11-001
  • AE-37
  • AEG-35156
  • aflibercept
  • afutuzumab
  • alemtuzumab
  • ALVAC-CEA/B7.1
  • alvocidib
  • AMG-386
  • Apomab
  • ARQ-197
  • AS-1411
  • astuprotimut-r
  • atiprimod dimaleate
  • ATN-224
  • AVX-701
  • belagenpumatucel-L
  • belinostat
  • bevacizumab
  • BP-GMAX-CD1
  • brentuximab vedotin
  • BZL-101
  • Cadi-05
  • canfosfamide hydrochloride
  • catumaxomab
  • CB-10-01
  • CBLC-102
  • CEA-TRICOM
  • cenersen
  • cetuximab
  • CG-201
  • cintredekin besudotox
  • CMLVAX-100
  • combretastatin A-4 prodrug
  • conatumumab
  • CS-1008
  • CTL901
  • CTP-37
  • CVac
  • DCVax-prostate
  • denosumab
  • dulanermin
  • E-75
  • farletuzumab
  • fowlpox-PSA vaccine
  • galiximab
  • GCS-100LE
  • gemtuzumab ozogamicin
  • girentuximab
  • GRN-163L
  • GRNVAC1
  • GV-1001
  • GV-1002
  • GVAX
  • GVX-3322
  • HE-3235
  • Her-2/Neu peptides
  • ibritumomab tiuxetan
  • idronoxil
  • IGN-101
  • ImmunoVEX tri-melan
  • IMO-2055
  • indisulam
  • INGN-225
  • INGN-241
  • INGN-401
  • inotuzumab ozogamicin
  • ipilimumab
  • ISIS-23722
  • kahalalide F
  • lonaprisan
  • lumiliximab
  • MAGE-3-TK
  • mapatumumab
  • ME-103
  • MGCD-0103
  • MGN-1601
  • MKC-1
  • motexafin gadolinium
  • MSI vaccine
  • MVA-BN
  • MVA-BN Her-2 vaccine
  • naptumomab estafenatox
  • necitumumab
  • nimotuzumab
  • Norelin
  • obinutuzumab
  • oblimersen sodium
  • ofatumumab
  • Onyvax-105
  • oregovomab
  • OTS-102
  • panitumumab
  • panobinostat
  • PANVAC-VF
  • PARP inhibitors
  • PAT-SC1
  • patupilone
  • PCI-24781
  • pDOM-PSMA27
  • PEP-223
  • pertuzumab
  • plitidepsin
  • poly-ICLC
  • PR1:169-177 peptide
  • PROSTVAC
  • PX-104.1
  • quarfloxacin
  • ramucirumab
  • Reditux
  • retaspimycin
  • Reximmune-C
  • Rh-Apo2L
  • rindopepimut
  • rituximab
  • sagopilone
  • SAI-EGF
  • seliciclib
  • Stimuvax
  • TG-4001
  • TG-4010
  • thymalfasin
  • tigapotide triflutate
  • TLN-232
  • trastuzumab
  • triciribine
  • TroVax
  • TRU-016
  • verpasep caltespen
  • voreloxin
  • VX-001
  • VX-944
  • XL-647
  • zalutumumab
  • zanolimumab
  • ZYC-300
Show More
Pricing
Get Notified
Email me when related reports are published